Close Menu

People in the News

Nov 17, 2020

Day Zero Diagnostics: Dekel Gelbman, Robin Patel, Sally Hojvat

Day Zero Diagnostics has appointed Dekel Gelbman as senior VP of business development and strategy, Robin Patel as a member of its scientific advisory board, and Sally Hojvat as a regulatory strategy advisor.

Gelbman joins the company from FDNA, where he was the founding CEO. Before that, he was a corporate and transactional attorney in Israel and the US.

Patel is the director of the infectious diseases research laboratory and co-director of the clinical bacteriology laboratory at the Mayo Clinic.

Hojvat is a senior consultant at Partners in Diagnostics. Prior to that, she was the director of the division of microbiology devices at the Center for Devices and Radiological Health at the US Food and Drug Administration.

Nov 17, 2020

Veracyte: John Hanna, Morten Frost

Veracyte has appointed John Hanna as its general manager of endocrinology, breast cancer, and lymphoma; and Morten Frost as its general manager of pulmonology. The firm has established the general manager structure as part of its plans for global expansion.

Hanna currently serves as Veracyte's chief commercial officer. Prior to Veracyte, Frost most recently held the role of head of global marketing for pathology and companion diagnostics at Agilent Technologies.

Nov 17, 2020

Inivata: Alan Schafer

Inivata has appointed Alan Schafer as its chief technology officer. Schafer previously served as CEO of 14M Genomics, a cancer molecular diagnostic firm. Prior to 14M Genomics, he served as CEO of Population Genetics. He has also served as global VP of technology development at GlaxoSmithKline and VP of genetics at Incyte. 

Nov 17, 2020

Sophia Genetics: Bram Goorden

Sophia Genetics has hired Bram Goorden as chief commercial officer and head of North American operations. Goorden, who will oversee expansion of the firm's global reach, joins Sophia from Foundation Medicine, where he was VP of international business and partnering. He previously served as general manager and head of therapeutics for Prometheus Laboratories.

Nov 16, 2020

Inteliquet: Tandy Tipps

Inteliquet has appointed Tandy Tipps as senior vice president of healthcare organizations solutions. In this role, Tipps will focus on advancing a site-centric approach to patient matching for clinical trials and precision medicine through a combination of technology, analytics, and clinical research expertise. Tipps previously developed and led the Oncology Site Network at Precision for Medicine. She also previously served as administrative director of a Phase I clinical trial program at the University of Texas MD Anderson Cancer Center.

Nov 13, 2020

Centogene: Jonathan Sheldon

Jonathan Sheldon has been nominated as a member of the supervisory board of Centogene. He will serve as an interim member with immediate effect until his confirmation at an upcoming shareholder meeting. Sheldon is senior VP of the digital insights business area at Qiagen and has led Qiagen's Digital Insights global business since 2018. Prior to this, he was global VP at Oracle Health Sciences.

Nov 10, 2020

Spartan Bioscience: Roger Eacock, Others

Spartan Bioscience, a Canadian company specializing in portable molecular diagnostic testing, has announced several new executive and board appointments. Roger Eacock joins the company as its new CEO and board member. Eacock has previously held leadership roles with companies such as TerrAscend, Sobeys, SunOpta, and Dell.

Eacock's appointment follows the election of three new members to Spartan's board of directors. Board Chair Rochelle Stenzler is a pharmacist with extensive experience as a senior executive in healthcare, retailing, consumer packaged goods, and interactive voice response technology. She has previously served as president of Revlon Canada and president and general manager of Pharma Plus Drugmarts.

Board member Arun Menawat is CEO of Profound Medical, which is developing a real-time MRI-guided thermal ultrasound system for incision-free ablation of abnormal or cancerous tissue. He is also former president and CEO of Novadaq Technologies.

Board member Maryscott Greenwood is partner and managing director of Crestview Strategy US, a public affairs consultancy. She is also CEO of the Canadian American Business Council.

Additionally, Lennie Ryer joins Spartan as CFO with more than 20 years of experience as CFO of several biotechnology companies including SQI Diagnostics and ConjuChem; and Trevor Brown joins Spartan as chief commercial officer, having previously served as vice president of precision medicine for Seracare Lifesciences and director of global strategic marketing at Luminex Molecular Diagnostics.

Finally, Jennifer Ross-Carriere has joined Spartan as chief legal and administrative officer. Ross-Carriere most recently served as general counsel, corporate secretary, and vice president, people and culture at IFS (previously Mxi Technologies).

Nov 06, 2020

Fluidigm: Puneet Suri

Fluidigm President and CEO Chis Linthwaite said during the company's third quarter earnings call that Puneet Suri has been named chief digital officer at Fluidigm. Suri has previously served as vice president, smart lab and digital science at Thermo Fisher Scientific, according to his LinkedIn profile. Prior to that he was senior director of software engineering at Life Technologies, which was acquired by Thermo Fisher, and before that, he spent a decade as a software development engineer and manager at Life Technologies predecessor Applied Biosystems.

Nov 05, 2020

Yourgene Health: Joanne Mason, Bill Chang

Joanne Mason has been promoted to CSO and director of Yourgene Health. Since joining the company in late 2019, she had been director of research and development. Previously, she was VP of biodiscovery at Cambridge Epigenetix and director of sequencing and sample acquisition at Genomics England. Mason holds a PhD in molecular and cellular biology from the University of Cambridge.

Bill Chang has taken on the role of chief entrepreneur at Yourgene Health while remaining a company director. In his new position, he will focus on new scientific collaborations and business ventures.

Nov 05, 2020

Micronoma: Eddie Adams, Greg Poore, Darryl Garrison

Micronoma has named Eddie Adams as chief scientific officer, company cofounder Greg Poore as chief analytic officer, and Darryl Garrison as chief operating officer.

Poore, now responsible for guiding further development of the firm's analytic and machine learning technology, is the first author of Micronoma's foundational Nature paper, a graduate of Duke University's biomedical engineering program, and currently a double-doctoral candidate in the University of California, San Diego's medical scientist training program.

Adams will lead the scientific development of Micronoma's diagnostic assays and its growing of the scientific team, with immediate responsibility for leading a utility trial for Micronoma's first offering, a diagnostic for the early detection of lung cancer. He holds a PhD from MIT and his background spans chemistry, immunology, nanotechnology, and molecular biology. He has developed diagnostics programs for the early detection of bloodstream infection and has extensive experience in sample preparation including commercializing methods and kits to extract nucleic acids for microbiome analyses.

Garrison holds more than 20 years of experience in the molecular diagnostic industry, having set up and run diagnostics laboratories at many of the major clinical cancer firms in Southern California. For Micronoma, he will establish the firm's CLIA labs, as well as assist with all processes and workflow implementation to ensure that the company is ready to process patient samples.

Nov 02, 2020

908 Devices: Kevin Hrusovsky

908 Devices, a company specializing in handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Kevin Hrusovsky as chairman of its board of directors. Hrusovsky has served on the company's board since 2013. He is currently chairman, CEO, and president of Quanterix, and is the founder of Powering Precision Health, a nonprofit global think tank composed of medical, research, and financial experts.

Nov 02, 2020

Scope Fluidics: Carl Wittwer

Carl Wittwer has been appointed to the advisory committee of Scope Fluidics. Wittwer, who is credited as one of the creators of PCR, has specialized in developing ultra-rapid PCR chemistries and was a co-founder of BioFire Diagnostics. Wittwer will advise the Warsaw, Poland-based firm in the futher development of its 15-minute sample-to-answer multiplex PCR One system for which it is currently developing SARS-CoV-2 assays. 

Oct 30, 2020

DotLab Scientific Advisory Board

DotLab, a women's health company developing a microRNA-based test for endometriosis, has formed its scientific advisory board. Appointees include Kristof Chwalisz, therapeutic area head urology, gynecology at Abbott Laboratories; Anula Jayasuriya, founder and managing director at EXXclaim Capital; Thomas Musci, former chief medical officer at Ariosa Diagnostics (acquired by Roche) and former faculty member at the University of California, San Francisco; Harold Sauer, chairman of the department of obstetrics and gynecology at Bridgeport Hospital, part of the Yale New Haven Health System; Eric Surrey, medical director at the Colorado Center for Reproductive Medicine; and Robert Taylor, professor of obstetrics and gynecology and assistant dean and director of the Md-PhD program at the University at Buffalo.

Oct 29, 2020

CareDx: Peter Maag, Reginald Seeto

CareDx announced that current Chairman and CEO Peter Maag will assume the role of executive chairman of the board, effective Nov. 1, and that current President and Chief Business Officer (CBO) Reginald Seeto will then assume the role of president and CEO. Seeto will also join the company's board.

Maag joined CareDx in 2012 as CEO and led the company through its IPO. Seeto joined CareDx in 2018 as president and CBO, leading the company's commercial, clinical, manufacturing, and R&D organizations. 

Oct 29, 2020

Prime Genomics: Robert Weigle

Prime Genomics, a company developing noninvasive testing to improve breast cancer detection, has named Robert Weigle as CEO. Weigle joins the firm from DigitalDx Ventures where he was an entrepreneur in residence. He has previously held senior-level sales and marketing positions at Johnson & Johnson, Baxter, and several startup ventures.

Oct 29, 2020

Qiagen: Jean-Pascal Viola

Qiagen has appointed Jean-Pascal Viola as senior vice president, head of the molecular diagnostics business area, in addition to his current role as leader of corporate business development and intellectual property and litigation, which he assumed in 2015. Viola will also continue to serve as a member of Qiagen's executive committee. He joined Qiagen in 2005 and has held various roles in Singapore, the US, and Germany. Since joining the business development team in 2007, he played a leading role in the acquisitions of Cellestis, Stat-Dx, NeuMoDx, and the assets of Forumlatrix related to digital PCR.

Oct 29, 2020

Clear Labs: Jeff Field

Clear Labs has hired Jeff Field to be its chief commercial officer. He has more than two decades of experience in healthcare and formerly was CCO at IDbyDNA and VP of oncology at Foundation Medicine. At Clear Labs, Field will oversee the continued commercialization of the company's tests including Clear Safety and Clear Dx nationally and internationally.

Oct 27, 2020

Inscripta: Sri Kosaraju

Inscripta has appointed Sri Kosaraju as its new president and CEO. Kosaraju succeeds Kevin Ness, who was the company's CEO since 2016, and who will remain as an advisor.

Kosaraju currently serves on the board of directors and is the chair of the audit committee of 10x Genomics. He also serves on the board of the nonprofit Testing for America. Prior to joining Inscripta, Kosaraju was president of Penumbra, and spent 16 years at JP Morgan, where he most recently served as head of Healthcare Equity Capital Markets and co-head of Technology Equity Capital Markets. 

Oct 23, 2020

Becton Dickinson: John DeFord, Patrick Kaltenbach, Dave Hickey

Becton Dickinson announced the retirement of Chief Technology Officer John DeFord, who joined BD with the acquisition of CR Bard in 2017. DeFord will be succeeded by Patrick Kaltenbach, who will serve as CTO and executive vice president. Kaltenbach joined BD as president of the life sciences segment in May 2018 after having most recently served as Agilent's senior vice president and president of that firm's life sciences and applied markets group. Dave Hickey, who currently serves as BD's worldwide president of integrated diagnostics solutions, will be promoted to the position of executive vice president and president of life sciences. The new appointments will be effective Jan. 1, 2021.

Oct 23, 2020

Biocept: Samuel Riccitelli

Biocept has appointed Samuel Riccitelli to its board of directors, effective immediately, and ahead of the planned retirement of Bruce Huebner, who will leave the board on Nov. 30, 2020Riccitelli boasts 35 years of experience in the molecular diagnostics industry, having served in executive-level positions and on the boards of multiple publicly traded companies. At Biocept, he will initially serve on the audit committee and the science and technology committee.

Riccitelli currently serves as an independent consultant to healthcare companies and is a director of OrthoPediatrics, a company focused on the orthopedic implant needs of children. Prior to that he was CEO of Pathnostics, a molecular diagnostics company focused on improving antibiotic stewardship. He also served as chairman of Precipio; president, CEO, and director of Signal Genetics; and executive VP and chief operating officer of Genoptix. Riccitelli received a BA from Washington and Jefferson College and an MS in engineering from The University of Texas.

Oct 08, 2020

Caris Life Sciences: Brian Lamon

Caris Life Sciences has appointed Brian Lamon as its chief business officer and head of biopharma business development. Lamon brings over 15 years of experience from large pharma and academia to the firm. He previously worked for Bristol Myers Squibb as a VP and development lead. Prior to that, he held several leadership roles in clinical development and business development for the same company.

Before joining industry, Lamon was assistant dean of research development and an assistant professor in the department of pathology and laboratory medicine at Weill Medical College of Cornell University in New York. He remains active on the faculty through a courtesy appointment as assistant professor.

Oct 07, 2020

New England Biolabs: Donald Comb

New England Biolabs founder Donald Comb has died. He founded NEB, one of the first biotechnology firms to commercialize restriction enzymes, in 1974 and served as its CEO until 2005, after which he remained chairman of the board of directors. Prior to NEB, he was a faculty member at Harvard Medical School. Comb held a PhD in biochemistry from the University of Michigan.

Oct 07, 2020

Nobel Prize: Emmanuelle Charpentier, Jennifer Doudna

Emmanuelle Charpentier and Jennifer Doudna have been jointly awarded the 2020 Nobel Prize in chemistry for their discovery and development of the CRISPR/Cas9 genome editing method.

"There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments," said Nobel Committee for Chemistry Chair Claes Gustafsson in a statement.

Charpentier is the director of the Max Planck Unit for the Science of Pathogens in Berlin. She holds a PhD from the Institute Pasteur in France.

Doudna is a professor at the University of California, Berkeley, and a Howard Hughes Medical Institute investigator. She holds a PhD from Harvard Medical School.

The two Nobel laureates will equally share the 10 million Swedish kronor ($1.12 million) award.

Oct 06, 2020

Pillar Biosciences: Robert Forrester

Pillar Biosciences, a next-generation sequencing cancer diagnostics company, has added Robert Forrester as an independent board member. Forrester has previously served as CEO of Verastem Oncology, COO of Forma Therapeutics, CEO and CFO of CombinatoRx, and CFO of Coley Pharmaceutical. He is also cofounder and chief experience officer of EQRx, which makes innovative medicines at dramatically lower prices for the benefit of society. Forrester has also served as managing director of the Proprietary Investment Group at MeesPierson.

Oct 06, 2020

Helio Health: Wei Li

Helio Health has appointed Wei Li to its advisory board. Li has more than 20 years of experience in bioinformatics research and development and is currently the endowed chair and professor of bioinformatics for the biological chemistry department at the University of California, Irvine's School of Medicine. He previously was the Dan L. Duncan Chair professor in the division of biostatistics at the Dan L. Duncan Cancer Center as part of the molecular and cellular biology department at the Baylor College of Medicine.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.